ATE395045T1 - Feste arzneizusammensetzungen mit gesteuerter wirkstoffabgabe hergestellt mittels eines thermoformverfahrens - Google Patents

Feste arzneizusammensetzungen mit gesteuerter wirkstoffabgabe hergestellt mittels eines thermoformverfahrens

Info

Publication number
ATE395045T1
ATE395045T1 AT00401825T AT00401825T ATE395045T1 AT E395045 T1 ATE395045 T1 AT E395045T1 AT 00401825 T AT00401825 T AT 00401825T AT 00401825 T AT00401825 T AT 00401825T AT E395045 T1 ATE395045 T1 AT E395045T1
Authority
AT
Austria
Prior art keywords
controlled release
compositions
polymethacrylate
active ingredients
thermoforming process
Prior art date
Application number
AT00401825T
Other languages
English (en)
Inventor
Patrick Wuthrich
Herve Rolland
Gilles Briault
Gerald Pichon
Francois Tharrault
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9547360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE395045(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE395045T1 publication Critical patent/ATE395045T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT00401825T 1999-06-28 2000-06-27 Feste arzneizusammensetzungen mit gesteuerter wirkstoffabgabe hergestellt mittels eines thermoformverfahrens ATE395045T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9908210A FR2795326B1 (fr) 1999-06-28 1999-06-28 Composition pharmaceutique solide thermoformable a liberation controlee

Publications (1)

Publication Number Publication Date
ATE395045T1 true ATE395045T1 (de) 2008-05-15

Family

ID=9547360

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00401825T ATE395045T1 (de) 1999-06-28 2000-06-27 Feste arzneizusammensetzungen mit gesteuerter wirkstoffabgabe hergestellt mittels eines thermoformverfahrens

Country Status (23)

Country Link
US (1) US6319520B1 (de)
EP (1) EP1064935B2 (de)
JP (2) JP2001031591A (de)
KR (1) KR100554899B1 (de)
CN (1) CN1174744C (de)
AT (1) ATE395045T1 (de)
AU (1) AU765885B2 (de)
BR (1) BR0002880A (de)
CA (1) CA2312545C (de)
CY (1) CY1110351T1 (de)
DE (1) DE60038848D1 (de)
DK (1) DK1064935T4 (de)
EA (1) EA003751B1 (de)
ES (1) ES2307489T5 (de)
FR (1) FR2795326B1 (de)
HK (1) HK1033435A1 (de)
HU (1) HU229342B1 (de)
NO (1) NO331449B1 (de)
NZ (1) NZ505431A (de)
PL (1) PL202494B1 (de)
PT (1) PT1064935E (de)
SI (1) SI1064935T2 (de)
ZA (1) ZA200003245B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607749B1 (en) * 1998-09-08 2003-08-19 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2818550B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controle de perindopril
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US7247313B2 (en) * 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US6656216B1 (en) 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
GB0117619D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
US7622146B2 (en) * 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
MXPA05011071A (es) 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
ES2336913T3 (es) 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
DE602005012244D1 (de) 2004-03-30 2009-02-26 Euro Celtique Sa Manipulationssichere dosierform mit einem adsorbens und einem adversen mittel
CA2601716C (en) 2004-06-25 2011-05-31 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
KR101387249B1 (ko) * 2006-02-03 2014-05-21 에보니크 룀 게엠베하 물에 난용성인 유효 성분과 중합체의 혼합물을 함유하는제약 조성물
EP2001350A4 (de) * 2006-03-20 2013-04-17 Teva Womens Health Inc Flexible komprimierte intravaginale ringe, verfahren zu ihrer herstellung und verwendung sowie gerät für ihre herstellung
US8069814B2 (en) 2006-05-04 2011-12-06 Advanced Cardiovascular Systems, Inc. Stent support devices
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
US7608737B2 (en) * 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
EP3045043B1 (de) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
EP2550863A1 (de) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis
EP2750666B1 (de) * 2011-08-30 2017-10-04 Universiteit Gent Mehrschichtige formulierungsfreisetzung
EP2872129B1 (de) 2012-07-16 2017-03-08 ratiopharm GmbH Komplex aus agomelatin und cyclodextrin
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
KR101659983B1 (ko) * 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
EP2810647A1 (de) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmazeutische Formulierungen, enthaltend Agomelatin in der Form des Co-Kristalls von Agomelatin mit organischer Säure
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
CN103724415B (zh) * 2013-12-31 2015-05-27 中山大学 斜带石斑鱼性别调控基因Rspo1及其制备方法和应用
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
FR3070619A1 (fr) 2017-09-01 2019-03-08 Ab7 Innovation Piece moulee monolithique en matrice multiple pour la diffusion d’actifs et son procede d’obtention
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
KR20200083500A (ko) * 2017-11-02 2020-07-08 이시하라 산교 가부시끼가이샤 서방성 의약 조성물
KR101856911B1 (ko) * 2017-12-13 2018-05-10 동국대학교 산학협력단 펠루비프로펜의 서방성 고체분산체 제제 및 이의 제조방법
CN109985025B (zh) * 2017-12-29 2023-01-13 沈阳药科大学 具有pH触发释药特征的眼部缓释给药系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1997008950A1 (en) † 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19539362A1 (de) † 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19728516C2 (de) * 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol
FR2766088B1 (fr) * 1997-07-17 2001-01-05 Dow Corning Sa Dispositifs a liberation controlee d'un agent pharmaceutique, leur fabrication par co-extrusion et article intermediaire
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee

Also Published As

Publication number Publication date
PT1064935E (pt) 2008-07-03
HUP0002469A3 (en) 2008-04-28
FR2795326A1 (fr) 2000-12-29
CN1174744C (zh) 2004-11-10
ZA200003245B (en) 2001-01-17
AU765885B2 (en) 2003-10-02
JP2006077033A (ja) 2006-03-23
CY1110351T1 (el) 2015-04-29
JP2001031591A (ja) 2001-02-06
DK1064935T3 (da) 2008-08-25
EP1064935B2 (de) 2011-06-08
ES2307489T3 (es) 2008-12-01
CA2312545A1 (fr) 2000-12-28
ES2307489T5 (es) 2011-11-07
NO20003349D0 (no) 2000-06-27
HUP0002469A2 (en) 2002-06-29
PL341042A1 (en) 2001-01-02
CA2312545C (fr) 2006-09-12
EP1064935A1 (de) 2001-01-03
HK1033435A1 (en) 2001-08-31
AU4273400A (en) 2001-01-04
US6319520B1 (en) 2001-11-20
FR2795326B1 (fr) 2001-08-31
EA200000584A2 (ru) 2000-12-25
CN1285188A (zh) 2001-02-28
KR100554899B1 (ko) 2006-02-24
HU229342B1 (en) 2013-11-28
NO331449B1 (no) 2012-01-02
PL202494B1 (pl) 2009-06-30
DE60038848D1 (de) 2008-06-26
SI1064935T1 (sl) 2008-08-31
EA200000584A3 (ru) 2001-04-23
DK1064935T4 (da) 2011-09-26
SI1064935T2 (sl) 2011-12-30
EA003751B1 (ru) 2003-08-28
KR20010049643A (ko) 2001-06-15
EP1064935B1 (de) 2008-05-14
NO20003349L (no) 2000-12-29
HU0002469D0 (en) 2000-08-28
NZ505431A (en) 2002-12-20
BR0002880A (pt) 2001-01-30

Similar Documents

Publication Publication Date Title
ATE395045T1 (de) Feste arzneizusammensetzungen mit gesteuerter wirkstoffabgabe hergestellt mittels eines thermoformverfahrens
CA2067754A1 (en) Preparation for the application of agents in mini-droplets
MXPA05010692A (es) Formulaciones que se adhieren a tejido.
ES2160577T3 (es) Nuevos esteres de aminoalcoholes biciclicos y triciclicos, su preparacion y su utilizacion en medicamentos.
AR017979A1 (es) Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento
ITMI942484A0 (it) Composizioni farmaceutiche a rilascio controllato osmotico e per diffusione del farmaco e procedimento per la loro preparazione
SE9703133D0 (sv) Pharmaceutical preparations for intranasal administration
WO2005065319A3 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
DE58906926D1 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung.
MX9305146A (es) Conjugado de interferon, procedimiento para su preracion y composicion farmaceutica que lo contienen.
CA2282082A1 (fr) Microgranules contenant du cisplatine
WO2003057176A3 (en) Porphyrins with virucidal activity
DE60320661D1 (de) System mit kontrollierter freisetzung bioaktiver wirkstoffe
NO910403L (no) Fremgangsmaate for fremstilling av farmasoeytisk preparat.
ES2174054T3 (es) Composiciones farmaceuticas acuosas liquidas que comprenden alginato sodico y bicarbonato potasico.
DE60235279D1 (de) Antitumorale mittel und verfahren zu ihrer herstellung
BRPI0417763A (pt) laminados elásticos respiráveis e métodos de fabricação dos mesmos
HUT60245A (en) Insecticidal compositions comprising 2-aryl-1-(alkoxymethyl)-4-halogen-5-(trifluoromethyl)-pyrrole derivatives as active ingredient and process for producing the active ingredient
JP6193846B2 (ja) パック
EP1023901A4 (de) Heilmittel für hepatitis c und dessen verwendung
DE69012924D1 (de) Azolsubstituierte Cycloalkanol-Derivate, Verfahren zu deren Herstellung und Anwendung dieser Derivate in der Landwirtschaft und im Gartenbau.
ATE298567T1 (de) Pharmazeutische zusammensetzung enthaltend ibuprofen und ein verfahren zur deren herstellung
ITMI942483A0 (it) Composizioni farmaceutiche a rilascio controllato osmotico e per diffusione del farmaco e procedimento per la loro preparazione
EP1161945A3 (de) Pharmazeutische Zusammensetzung enthaltend Prolin, Glycin und Lysin zur Behandlung von Sehnenverletzungen und offenen Wunden
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064935

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1064935

Country of ref document: EP